- About TapImmune
- News & Media
- Contact Us
JACKSONVILLE, Florida, October 7, 2015 /PRNewswire/ – TapImmune, Inc. (TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, will be featured...
A personal perspective from Dr Glynn Wilson, Chairman & CEO, TapImmune National Breast Cancer Awareness Month (NBCAM), We start October on a high note. On September 15, TapImmune and the Mayo Clinic announced the award of a $13.3 million grant from the US Department of Defense Breast Cancer...